Drug Approval | November 13, 2024
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The company uses iPS cells to develop treatments for diseases relating to the kidney
US Generics grew 5% to Rs. 467 Crores for the quarter
Subscribe To Our Newsletter & Stay Updated
